PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Vaccine, gene therapy makers fall after Peter Marks resignation Promising Phase 2 Results and Revenue Potential Drive Buy Rating for BioNTech’s BNT327 in SCLC PremiumCompany AnnouncementsBioNTech’s Earnings Call: Oncology Growth Amidst Challenges BioNTech price target lowered to $151 from $172 at Truist BioNTech SE: Navigating Near-Term Challenges with Strategic Pipeline Opportunities and Long-Term Growth Potential PremiumRatingsCautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline Uncertainty BioNTech price target lowered to $143 from $147 at BofA BNTX Earnings: BioNTech Stock Slips Despite Q4 Beats 
